24 dated developments that affect people paying cash for GLP-1 treatment, newest first. Each item links to its primary source; "reported" means the item comes from a news report rather than an official document.

Latest developments

Our November re-read of the ten programs we review

· confirmed (our first-party reads)

We re-read the ten programs' own pages on November 20 and 21, 2026. Found cut its cash prices (tirzepatide $339 a cycle month to month, $199 on 12 months), Mochi Health now prints compounded prices by dose plus a $49 to $79 monthly membership, Noom Med published a tirzepatide price ($299 a month billed per 12 weeks), Henry Meds no longer prints an injectable tirzepatide price, and Hims & Hers lists brand drugs only. Ro blocked us again.

What it means for cash-pay patients: Prices and rankings on this site now use these reads; each review has a "What changed" box.

Source: Transparency index and price index (sources listed there)

Five states join the FTC lawsuit against Hims & Hers

· confirmed

An amended complaint added Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs in the case the FTC, Utah and Los Angeles County (for the People of California) filed on July 29, 2026. The FTC's case page lists the case as pending; the allegations are unproven.

What it means for cash-pay patients: Nothing changes for customers' accounts; the case concerns billing, cancellation and data practices.

Source: FTC press release

FDA requires a NAION (optic-nerve) warning on all approved GLP-1 labels

· confirmed

FDA's Drug Safety Communication requires every approved GLP-1 receptor agonist, including Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy to its warnings. In FDA's meta-analysis of 126 trials the rate was 6.4 versus 3.8 cases per 100,000 person-years. Compounded products are not mentioned.

What it means for cash-pay patients: Sudden, painless vision loss in one eye on any GLP-1 means calling a clinician right away.

Source: FDA Drug Safety Communication

Hims & Hers 10-Q: FTC motion to dismiss set for hearing January 14, 2027

· confirmed

Hims & Hers' quarterly report says the motion to dismiss it filed on October 22, 2026 "is currently set for hearing on January 14, 2027", that it accrued about $60 million for the matter as of September 30, and that compounded GLP-1s are now offered "on a limited scale". Our November 8 pages gave a January 7 hearing date from the docket; we corrected it.

What it means for cash-pay patients: The case is unresolved; read Hims' cancellation terms before you subscribe.

Source: Hims & Hers Form 10-Q

Lilly and Hims & Hers: Zepbound and Foundayo at Lilly's self-pay prices

· confirmed

Lilly and Hims said eligible Hims patients can buy Zepbound (from $299 a month) and Foundayo (from $149) at Lilly's self-pay prices without leaving the Hims platform, and Hims committed not to offer compounded copies of Lilly's GLP-1s. The release states no membership fee; Hims' own page charges a $149 monthly membership after a $39 first month.

What it means for cash-pay patients: Add the Hims membership to Lilly's price when you compare.

Source: Lilly and Hims & Hers release

NAD asks Good Life Meds to drop health and "personalized" claims for compounded tirzepatide

· confirmed

In a challenge brought by Lilly, BBB National Programs' National Advertising Division recommended that Good Life Meds stop health-benefit and "personalized" or "custom formulated" claims for its compounded "Tirzepatide+" products. Good Life said it disagrees but will comply. NAD is industry self-regulation, not a court or FDA.

What it means for cash-pay patients: Ask what is in a "plus" vial and what evidence supports any added ingredient.

Source: BBB National Programs decision

Medicare's $274 negotiated price for Ozempic, Rybelsus and Wegovy starts January 1, 2027

· confirmed

CMS lists a maximum fair price of $274 for a 30-day supply of Ozempic, Rybelsus and Wegovy, effective January 1, 2027, inside Medicare Part D. It is separate from the $50 Medicare GLP-1 Bridge copay.

What it means for cash-pay patients: Medicare only: it does not change cash prices at NovoCare, pharmacies or telehealth programs.

Source: CMS fact sheet

FDA warning letter to RonanRx over "FDA-approved compounded" and "American made" claims

· confirmed

FDA's letter 737905 (posted November 3) says RonanRx's website and X account made false or misleading claims about compounded semaglutide and tirzepatide, and that FDA's records list no U.S.-registered manufacturer of semaglutide or tirzepatide active ingredient for compounding.

What it means for cash-pay patients: Treat "FDA-approved compounded" or "made in America" claims as red flags.

Source: FDA warning letter 737905

Class II recall of compounded GLP-1 combination vials from Victory Medical Center Pharmacy

· confirmed

FDA's enforcement report of November 11 lists a voluntary recall of semaglutide and tirzepatide vials with added L-carnitine, niacinamide or B6 from Victory Medical Center Pharmacy in Austin, Texas, for "Lack of Processing Controls", distributed in Colorado, Florida and Texas. It follows October recalls from Carolina Infusion, Apothecary Pharma and Houston Rx.

What it means for cash-pay patients: Check the pharmacy name and lot on your vial label and ask your program.

Source: FDA enforcement reports (openFDA)

HHS draft enforcement-discretion policy for six compounded peptides, including BPC-157

· confirmed (peptide names reported)

A Federal Register notice (91 FR 68526) announced a draft HHS policy not to take enforcement action against 503A compounding with peptides listed in its appendix; law-firm summaries list BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. No GLP-1 is covered.

What it means for cash-pay patients: It does not change the status of semaglutide or tirzepatide.

Source: Federal Register

KFF: 18% of large employers cover GLP-1s for weight loss

· confirmed

KFF's 2026 Employer Health Benefits Survey finds 18% of firms with 200 or more workers cover GLP-1 drugs primarily for weight loss, and 12% of large firms that do not cover them say they stopped in the past 12 months.

What it means for cash-pay patients: Most workers at large employers still pay cash for weight-loss GLP-1s.

Source: KFF Employer Health Benefits Survey 2026 (PDF)

NexLife sets microdose prices equal to its standard plans

· confirmed

NexLife's microdose program pages now list microdose tirzepatide at $129 month to month and $125, $119 or $115 a month on 3-, 6- or 12-month plans, and microdose semaglutide at $109, $105, $99 or $95, the same as the standard plans. On October 15 the microdose tirzepatide tiles were $189 down to $147 and the semaglutide figures conflicted across pages.

What it means for cash-pay patients: Microdose and standard plans now cost the same; sublingual ODT prices did not change.

Source: NexLife microdose program pages

NexLife lowers its standard compounded prices

· confirmed

NexLife's plan pages now list compounded tirzepatide at $129 month to month and $125, $119 or $115 a month on 3-, 6- or 12-month plans, and semaglutide at $109, $105, $99 or $95. On October 15 the same plans were $169–$139 and $139–$119. Microdose and sublingual prices did not change that day.

What it means for cash-pay patients: Eden Health's $129 tirzepatide now equals NexLife's month-to-month price.

Source: NexLife plan pages

Hims & Hers FTC case: initial case management conference held

· confirmed

The federal court in San Francisco held the initial case management conference in FTC, Utah and Los Angeles County v. Hims & Hers. Hims had moved to dismiss on October 22; the hearing on that motion was then set for January 7, 2027; Hims' 10-Q of November 9, 2026 gives January 14, 2027.

What it means for cash-pay patients: No ruling has been made; the allegations are unproven.

Source: CourtListener docket 3:26-cv-07871

Hims & Hers moves to dismiss the FTC lawsuit

· confirmed

Hims & Hers asked the court to dismiss the complaint filed July 29 by the FTC, Utah and Los Angeles County. The opposition is due November 25 and the reply December 17.

What it means for cash-pay patients: Customers' accounts are not affected by the filing; see our explainer.

Source: CourtListener docket

Medicare Open Enrollment opens

· confirmed

Medicare Open Enrollment runs October 15 to December 7, 2026, with changes effective January 1. The Medicare GLP-1 Bridge ($50 copay) covers Foundayo, Wegovy and the Zepbound KwikPen for eligible enrollees through December 31, 2027.

What it means for cash-pay patients: People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1.

Source: Medicare.gov

CNN reports GLP-1 prescribing to people with anorexia via telehealth

· reported

CNN reported clinicians seeing more anorexia patients using GLP-1s, many obtained through telehealth. Hims & Hers told CNN that eating-disorder screening is mandatory in its prescribing process.

What it means for cash-pay patients: Expect more scrutiny of asynchronous intake.

Source: CNN

Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027

· reported

CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes, and still not cover GLP-1s for weight loss.

What it means for cash-pay patients: Employees seeking a weight-loss GLP-1 stay in the cash-pay market. Details come from news reports, not a Walmart plan document.

Source: CNBC

FDA updates its page on unapproved GLP-1 drugs

· confirmed

FDA's consumer page (current as of October 1, 2026) lists telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, a warning about semaglutide salt forms, and states that retatrutide and cagrilintide cannot be used in compounding.

What it means for cash-pay patients: Check the vial's beyond-use date and discard 28 days after first use unless labelled otherwise.

Source: FDA

Rhode Island Medicaid ends weight-loss-only GLP-1 coverage

· confirmed

Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed only for weight loss, effective October 1, 2026; coverage continues for type 2 diabetes and other approved uses.

What it means for cash-pay patients: Affected members move to self-pay or stop.

Source: Tufts Health RITogether provider notice

Medicare GLP-1 Bridge extended through 2027

· confirmed

CMS's BALANCE model page (modified September 29, 2026) states "The Medicare GLP-1 Bridge has been extended through December 31, 2027" and includes an FAQ about "the BALANCE Model not launching in Medicare in 2027".

What it means for cash-pay patients: Eligible Part D enrollees keep the $50 copay through 2027.

Source: CMS

FDA warning letter to Empower Pharmacy

· confirmed

FDA warning letter 738238 (dated September 18, posted September 22, 2026) says Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions.

What it means for cash-pay patients: Ask your program which pharmacy fills your prescription.

Source: FDA

FTC, Utah and Los Angeles County sue Hims & Hers

· confirmed

The FTC and two state and local co-plaintiffs sued Hims & Hers in federal court, alleging it charged consumers without a provider consultation, did not clearly disclose refills, made cancellation hard and shared health data with advertising platforms. Hims called the claims baseless.

What it means for cash-pay patients: Allegations only; see our explainer.

Source: court docket, FTC v. Hims & Hers (CourtListener)

FDA proposes to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list

· confirmed

FDA proposed (91 FR 23431) not to place the three drugs on the list of bulk substances 503B outsourcing facilities may use; the comment period closed July 30, 2026 (91 FR 38719). No final decision was found as of November 20, 2026.

What it means for cash-pay patients: 503A patient-specific compounding is not covered by this proposal.

Source: Federal Register

No material verified change was found between October 11 and November 20, 2026 in state telehealth or compounding rules, in compounded-program price announcements, or in Medicaid coverage beyond the items above. Older items from earlier versions of this page were dropped because their sources were not recorded. Price changes are tracked in the price index; the Hims case is explained in our FTC lawsuit article.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.